Alnylam Pharmaceuticals Projects $4.2B–$4.5B in 2026 TTR Sales Amid Q3 Revenue Growth
Alnylam Pharmaceuticals (ALNY) reported a significant increase in third-quarter product revenues, which grew 52% year-over-year to approximately $1.3 billion. This growth was primarily driven by the continued market uptake of AMVUTTRA. Despite the strong revenue figures, CEO Yvonne Greenstreet noted that management is not yet fully satisfied with the underlying demand growth observed. Looking ahead, the company provided long-term guidance for its TTR (transthyretin) franchise, anticipating sales between $4.2 billion and $4.5 billion by 2026. Additionally, Alnylam is expanding its TRITON-CM program to reach approximately 2,250 patients while maintaining its projected launch timeline around 2030.
Tickers: $ALNY
Topics: management commentary product revenue quarterly earnings
Read the full article at Seeking Alpha
Part of the story Vanda Pharmaceuticals Projects 2026 Revenues Exceeding $240 Million Following Q3 Growth (3 articles)